<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514033</url>
  </required_header>
  <id_info>
    <org_study_id>108344</org_study_id>
    <nct_id>NCT00514033</nct_id>
  </id_info>
  <brief_title>A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children</brief_title>
  <official_title>Open, Multicentric, PMS Study to Monitor Safety and Reactogenicity of GlaxoSmithKline Biologicals' Poliomyelitis Vaccine (Inactivated)-Poliorix, Administered in Korean Children as a Primary Vaccination in Healthy Subjects Aged 2 to 6 Months or as a Booster Vaccination in Subjects Aged 4 to 6 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Following licensing of PoliorixTM in Korea, this study will collect safety data about the
      routine use of this vaccine in 600 children according to the regulations of Korean Food and
      Drugs Administration (KFDA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open, multicentric, post-marketing surveillance study to monitor the safety and
      reactogenicity of GlaxoSmithKline Biologicals. Poliomyelitis vaccine (inactivated)
      -PoliorixTM., administered in Korean children as a primary vaccination in healthy subjects
      aged two to six months or as a booster vaccination in subjects aged four to six years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of unsolicited adverse events.</measure>
    <time_frame>During 7 days (Day 0 - 6) following vaccination.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs).</measure>
    <time_frame>During the entire study period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local and general adverse events.</measure>
    <time_frame>During 7 days (Day 0 to 6) after vaccination</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">349</enrollment>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Poliomyelitis vaccine (inactivated) -PoliorixTM</intervention_name>
    <description>Deep intramuscular injections for the primary vaccination and booster vaccination.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korean children between two and six months of age (primary vaccination) or between four and
        six years of age (booster vaccination) at the time of vaccination.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy male or female child between two and six months of age (primary vaccination)
             or between four and six years of age (booster vaccination) at the time of vaccination.

          -  Subjects for whom the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol (e.g. completion of the diary cards)

          -  Written informed consent obtained from the parent/ guardian of the subject

        Exclusion Criteria:

          -  At the time of study entry, the contraindications and precautions of use indicated in
             the Korean Label should be checked and the subject must not be included in the study
             if there is any contraindication or risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

